Novartis Deals in Cardio Again, Dropping $1.4B to Acquire Tourmaline

By /

Novartis has been investing heavily in its cardiovascular pipeline this year, forging partnerships with Flagship startup ProFound Therapeutics and China’s Argo Biopharmaceutical, among others.

Scroll to Top